<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502017</url>
  </required_header>
  <id_info>
    <org_study_id>TCAI_LAAO</org_study_id>
    <nct_id>NCT04502017</nct_id>
  </id_info>
  <brief_title>Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion</brief_title>
  <acronym>FADE-DRT</acronym>
  <official_title>Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Cardiac Arrhythmia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Cardiac Arrhythmia Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison among three different antithrombotic strategies after percutaneous LAA occlusion&#xD;
      with a Watchman FLX LAAC device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data on the optimal antithrombotic therapy (AT) after percutaneous left atrial appendage&#xD;
      (LAA) occlusion are still scarce. The classical AT strategy after LAA occlusion includes&#xD;
      6-weeks of warfarin + aspirin followed by dual anti platelet therapy with clopidogrel (75 mg)&#xD;
      and aspirin (81-325 mg) until 6 months of follow-up, then aspirin alone is continued&#xD;
      indefinitely. Nonetheless, a significant number of patients continues to suffer from&#xD;
      device-related thrombosis which carries a high risk of thromboembolic events. Other AT&#xD;
      strategies have been tested in order to reduce the risk of thrombus-formation on device.&#xD;
      Among them, replacement of clopidogrel with half-dose oral anticoagulation (OAC) in patients&#xD;
      with genetic resistance to this drug has been recently reported to reduce the incidence of&#xD;
      DRT. Additionally, reduced dose of novel OAC was demonstrated to lead to lower thrombin&#xD;
      generation compared to DAPT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Stroke, Systemic Embolism, and Device-related Thrombosis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Major Bleeding Events</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Minor Bleeding Events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Device-Related Thrombosis</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Left Atrial Appendage Occlusion</condition>
  <arm_group>
    <arm_group_label>Standard Antithrombotic Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genetic-Tailored AntiThrombotic Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Half-Dose NOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half Dose of Novel OAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA plus Clopidogrel</intervention_name>
    <description>OAC (6 weeks) + DAPT (until 6 months) + ASA</description>
    <arm_group_label>Standard Antithrombotic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genetic-Tailored AntiThrombotic Strategy</intervention_name>
    <description>Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype</description>
    <arm_group_label>Genetic-Tailored AntiThrombotic Strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half-Dose of novel OAC</intervention_name>
    <description>Half Dose of novel OAC post-device Implantation</description>
    <arm_group_label>Half-Dose NOAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women â‰¥18 years of age&#xD;
&#xD;
          -  Successful LAAC procedure (device implanted without procedural or bleeding&#xD;
             complication).&#xD;
&#xD;
          -  Patients contraindicated or unsuitable for long-term OAC.&#xD;
&#xD;
          -  History of AF (permanent or persistent or paroxysmal).&#xD;
&#xD;
          -  Written informed consent by the patient or designee if the patient is unable to&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt; 2 years.&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to practice birth control during participation&#xD;
             in the study.&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Domenico G Della Rocca, MD</last_name>
    <phone>7375296806</phone>
    <email>domenicodellarocca@hotmail.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Natale, MD</last_name>
    <phone>5127842651</phone>
    <email>andrea.natale@stdavids.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Natale, MD</last_name>
      <email>andrea.natale@stdavids.com</email>
    </contact>
    <contact_backup>
      <last_name>Domenico G Della Rocca, MD</last_name>
      <phone>7375296806</phone>
      <email>domenicodellarocca@hotmail.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Cardiac Arrhythmia Research Foundation</investigator_affiliation>
    <investigator_full_name>Andrea Natale</investigator_full_name>
    <investigator_title>Executive Medical Director</investigator_title>
  </responsible_party>
  <keyword>left atrial appendage</keyword>
  <keyword>Watchman</keyword>
  <keyword>antithrombotic therapy</keyword>
  <keyword>device-related thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

